Better Treatment Through Research

Leukemia and Myeloma Program

Our Mission

To understand disease biology and translate research discoveries into more effective diagnostic and treatment solutions for people affected by blood cancers in B.C.

About Leukemia and Myeloma


Over 6,000 new cases of leukemia are currently being diagnosed in Canada every year with a projected doubling of that number in the next 2 decades. With present treatments (that have barely changed in 3 decades), overall 5-year survival rates are at best ~50% (the 9th worst prognosis for all cancer types) and the long-term quality of life in many of these survivors is significantly compromised. Clearly new treatment strategies are urgently needed.


Multiple Myeloma is a blood cancer that is associated with the abnormal behavior and uncontrolled growth of white blood cells. > 2200 Canadians are newly diagnosed in Canada per year and the disease remains relatively unknown. To date there is no cure, but advancements in research and treatment are enabling patients to live better and longer lives than before.

Latest News

Jan 10, 2020

New insights into the role of microRNAs and their regulation of normal and aberrant blood development

MicroRNAs (miRNAs) are commonly deregulated in acute myeloid leukemia (AML), affecting critical genes not only through direct targeting, but also through modulation of downstream effectors. Homeobox (Hox) genes balance self-renewal, proliferation, cell death, and differentiation in many tissues and aberrant Hox gene expression can create a predisposition to leukemogenesis in hematopoietic cells. However, possible linkages between the regulatory pathways of Hox genes and miRNAs are not yet fully resolved.

Back to top